Clinical relevance of symptomatic superficial-vein thrombosis extension: lessons from the CALISTO study

Alain Leizorovicz, François Becker, Andrea Buchmüller, Isabelle Quéré, Paolo Prandoni and Hervé Decousus
Clinical relevance of symptomatic superficial-vein thrombosis extension: lessons from the CALISTO study

Alain Leizorovicz,1 François Becker,2 Andrea Buchmüller,3 Isabelle Quéré,4 Paolo Prandoni,5 and Hervé Decousus,3 for the CALISTO Study Group

1Unité Mixte de Recherche/Centre National de la Recherche Scientifique 5558, Faculté de Médecine René Thomas Hyacinthe Laennec, University of Lyon, Lyon, France; 2Division of Angiology and Hemostasis, University Hospital, Geneva, Switzerland; 3Institut National de la Santé et de la Recherche Médicale, Centre d’Investigation Clinique/Epidémiologie Clinique-3, EA3065, and Department of Medicine and Therapeutics, North Hospital, Saint Etienne University Hospital, Saint Etienne, France; 4Institut National de la Santé et de la Recherche Médicale, Centre d’Investigation Clinique 1001, EA2992, and Vascular Medicine Department, Saint Eloi Hospital, Montpellier University Hospital, Montpellier, France; and 5Thromboembolism Unit, University of Padua, Padua, Italy

Key Points

• Symptomatic extensions, whether or not reaching the SFJ, are common complications of SVT.
• Their frequency and associated risk of venous thromboembolic complications and medical resource consumption are reduced by fondaparinux.

Introduction

Spontaneous, acute, symptomatic superficial-vein thrombosis (SVT) of the legs, with no deep-vein thrombosis or pulmonary embolism at presentation (ie, isolated), is now recognized as a frequent disease with the potential of leading to severe thromboembolic complications.1-4 The Comparison of Arixtra in lower Limb Superficial vein Thrombosis with placebo (CALISTO; a complete list appears in the supplemental Appendix) study showed that a 45-day subcutaneous once-daily treatment with fondaparinux 2.5 mg was associated with an 85% relative reduction in the risk of the composite of symptomatic pulmonary embolism, symptomatic deep-vein thrombosis, symptomatic SVT recurrence, or symptomatic SVT extension at 3 cm or less from the sapheno-femoral junction (SFJ), a benefit that was maintained at 30 days follow-up.5

While there is no doubt that preventing deep-vein thrombosis or pulmonary embolism is an important therapeutic goal,6 the clinical relevance of preventing SVT extensions is controversial. In CALISTO, a cutoff value of 3 cm from the SFJ was chosen for defining SVT extension because most authors and consensus groups emphasize that extensions involving the SFJ are associated with an increased risk of thrombus propagation into the deep venous system.7-12 However, few data are available describing the natural history of patients presenting with a SVT extension, whether this progressed to within ≤3 cm or to >3 cm from the SFJ, and the optimal therapeutic strategy to manage this complication remains unclear.

With a unique opportunity to use the CALISTO database, our primary objective was therefore to examine the practice management and outcome of patients with any type of symptomatic extension of spontaneous, acute, symptomatic, isolated SVT of the legs and to assess the effect of fondaparinux on such complications.

Methods

The present study is based on a post hoc analysis of the CALISTO database. The methods used in CALISTO have been described elsewhere6 and are summarized below.

The clinical relevance of symptomatic extension of spontaneous, acute, symptomatic, lower-limb superficial-vein thrombosis (SVT) is debated. We performed a post hoc analysis of a double-blind trial comparing fondaparinux with placebo. The main study outcome was SVT extension by day 77, whether to ≤3 cm or >3 cm from the sapheno-femoral junction (SFJ). All events were objectively confirmed and validated by an adjudication committee. With placebo (n = 1500), symptomatic SVT extension to ≤3 cm or >3 cm from the SFJ occurred in 54 (3.6%) and 56 (3.7%) patients, respectively, inducing comparable medical resource consumption (eg, anticoagulant drugs and SFJ ligation); subsequent deep-vein thrombosis or pulmonary embolism occurred in 9.3% (5/54) and 8.9% (5/56) of patients, respectively. Fondaparinux was associated with lower incidences of SVT extension to ≤3 cm (0.3%; 5/1502; P <.001) and >3 cm (0.8%; 12/1502; P <.001) from the SFJ and reduced related use of medical resources; no subsequent deep-vein thrombosis or pulmonary embolism was observed in fondaparinux patients. Thus, symptomatic extensions are common SVT complications and, whether or not reaching the SFJ, are associated with a significant risk of venous thromboembolic complications and medical resource consumption, all reduced by fondaparinux. This trial was registered at www.clinicaltrials.gov: NCT00443053. (Blood. 2013;122(10):1724-1729)
Patients
Hospitalized or nonhospitalized patients aged ≥18 years with an acute, symptomatic lower-limb SVT at least 5 cm long, confirmed by standardized compression ultrasonography, were eligible for randomization. The main exclusion criteria were documented symptomatic or asymptomatic deep-vein thrombosis or documented symptomatic pulmonary embolism at presentation, SVT located within 3 cm from the SFJ, documented history of SVT within the last 6 months, deep-vein thrombosis or pulmonary embolism within the last 6 months, or active cancer within the last 6 months, and any conditions favoring bleeding.

Study design and treatments
CALISTO was an international (European), multicenter, randomized (centrally), double-blind, placebo-controlled study evaluating the efficacy and safety of fondaparinux sodium 2.5 mg once daily for 45 days. The day of randomization was defined as day 1. Follow-up visits were scheduled at days 10 ± 2, 30 ± 2, 45 ± 2, and 75 ± 2. Routine ultrasonographic examinations were discouraged during follow-up.

Study medications were packaged in identical boxes,1 per patient, containing sufficient visually identical, prefilled, 0.5-ml single-dose syringes of either fondaparinux sodium 2.5 mg (Arixtra, GlaxoSmithKline) or placebo (sodium chloride) to allow 45-day treatment. Self-administration was encouraged, but the final decision was left to the investigator’s discretion.

The use of graduated compression stockings was encouraged for all patients. In addition, patients were free to take paracetamol (acetaminophen) or topical nonsteroidal antiinflammatory drugs as needed. Concomitant therapy interfering with the study treatments was prohibited throughout the study, in particular, the use of any other anticoagulant agent, more than 1 antiplatelet agent, aspirin at doses >325 mg per day, oral nonsteroidal antiinflammatory drugs, and topical heparins or heparinoids. The management of venous thromboembolic events occurring during follow-up was left to the investigator’s discretion.

The study was conducted according to the ethical principles stated in the Declaration of Helsinki and local regulations. An independent ethics committee approved the protocol, and written informed consent was obtained from all patients before randomization.

Outcome measures
The main outcome investigated in this post hoc analysis was ultrasonographically confirmed symptomatic extension of the index SVT reported by the investigators up to day 77 and validated by the central adjudication committee as being an extension. Extension was defined as downstream (proximal) propagation of the initial thrombus by at least 2 cm. We considered 2 types of extension: those progressing to within 3 cm from the SFJ, which were a component of the composite primary efficacy outcome of the CALISTO study,5 and those not reaching the SFJ, that is, located at >3 cm from the saphenofemoral junction.

We also included as outcomes the incidence of symptomatic pulmonary embolism and symptomatic deep-vein thrombosis occurring subsequent to a symptomatic extension, whether to <3 cm or to >3 cm from the saphenofemoral junction, and the incidence of the composite of symptomatic pulmonary embolism, symptomatic deep-vein thrombosis, and symptomatic SVT recurrence or any symptomatic extension up to day 77. The management of symptomatic extensions was described. All outcomes were prospectively recorded during the CALISTO trial.

Symptomatic pulmonary embolism was confirmed by ventilation-perfusion scanning, helical computed tomography, pulmonary angiography, or autopsy. Symptomatic deep-vein thrombosis was confirmed by ultrasonography or venography. Recurrence was defined as a new thrombus located in a different superficial vein and not directly contiguous upstream with the index thrombus or located in the same superficial vein but separated from the index thrombus by at least 10 cm. All symptomatic extensions or symptomatic recurrences of SVT were confirmed by ultrasonography. All duplex ultrasonographic examinations were performed according to a predefined procedure standardized across all centers,13-15 summarized in the supplemental Appendix.

Finally, all symptomatic thromboembolic complications listed above were reviewed by a central adjudication committee, the members of which were unaware of the patients’ group assignments.

Statistical analysis
All analyses were performed on data from the intention-to-treat population of CALISTO, defined as all randomized patients (n = 3002). Patients for whom an efficacy assessment was lacking (ie, those for whom no information on their status with respect to thromboembolic complications at the end of the study was recorded) were assumed not to have experienced any event. The time for evaluation in this post hoc analysis was at day 77.

Statistical analysis was performed using SPSS software (version 19.0; IBM, Armonk, NY). The Fisher exact test was used for categorical variables, and the Wilcoxon signed-rank test was used for continuous variables. P values were calculated, Absolute differences and relative risks, with 95% CIs, were also presented.

Role of the funding source
GlaxoSmithKline funded the study. A steering committee was responsible for the design, conduct, and reporting of the study. Data were collected and analyzed by the study sponsor. An independent central adjudication committee managed the database of adjudicated outcomes. All authors contributed to designing this post hoc analysis; had full access to the data and analyses; contributed to interpreting the data and developing the report; agreed on the final version of the manuscript; and had final responsibility for the report content and decision to publish the findings.

Results
Study population
The CALISTO study enrolled 3002 patients between March 2007 and May 2009, of whom 1500 and 1502, respectively, were randomized to the placebo and fondaparinux groups. Demographic and clinical characteristics, prestudy medications and interventions, treatment duration and compliance, and the use of most other treatments during the study were well balanced between the 2 groups and have been described elsewhere.5 However, placebo-treated patients received anticoagulant therapy and underwent surgery for SVT more frequently than fondaparinux-treated patients during the study (6.4% vs 1.1% and 4.1% vs 1.0%, respectively).5

Symptomatic SVT extension in the placebo group
Symptomatic extension of the index SVT occurred in 109 of 1500 patients (7.3%) in the placebo group (Figure 1). The head of the thrombus extension was at ≤3 cm from the SFJ in 54 (3.6%) patients and at >3 cm from the SFJ in 56 (3.7%); 55/56 of the latter having occurred by day 47.

Overall, placebo-treated patients with a SVT extension to >3 cm from the SFJ received as many treatments in addition to the study drug as patients with a SVT extension to ≤3 cm from the SFJ (Table 1). In particular, anticoagulants were used in more than 50% (mainly at therapeutic doses) and oral antiinflammatory agents in more than 20% of patients for both categories of SVT extension. Patients with extensions not involving the SFJ attended fewer face-to-face visits (in addition to those scheduled in the study protocol) after event diagnosis. However, these patients underwent more compression ultrasonography examinations to follow up the extension after diagnosis than patients with an extension to ≤3 cm from the SFJ. Moreover, they were less frequently hospitalized after event
diagnosis or treated surgically for superficial-vein thrombosis. However, when hospitalized or operated on, the duration of hospitalization and the types of intervention (mainly ligation of the SFJ) were similar in patients with a SVT extension to >3 cm from the SFJ and those with an extension to ≤3 cm from the SFJ. Interestingly, of 6 (11.1%) placebo-treated patients with a SVT extension to ≤3 cm from the SFJ and 14 (25.0%) placebo-treated patients with a SVT extension to >3 cm from the SFJ, none received any anticoagulant treatment nor underwent surgery.

In placebo-treated patients with extension, the risk of subsequent deep-vein thrombosis or pulmonary embolism was similar whether the extension progressed to ≤3 cm or >3 cm from the SFJ: 9.3% (5 of 54 patients, proximal deep-vein thrombosis in 4 patients and pulmonary embolism in 1) and 8.9% (5 of 56 patients, deep-vein thrombosis in 3 patients, proximal in 1 and distal in 2, and pulmonary embolism in 2), respectively.

Overall, symptomatic venous thromboembolic complications, that is, the composite of symptomatic deep-vein thrombosis, pulmonary embolism, and SVT recurrence or extension (irrespective of the distance of the head of the extension from the SFJ), occurred in 141 of 1500 patients (9.4%) in the placebo group.

**Fondaparinux effect on the incidence, management, and thrombotic complications of symptomatic SVT extension**

Symptomatic extension of the index SVT occurred in 17 of 1502 patients (1.1%) in the fondaparinux group (relative risk fondaparinux vs placebo: 0.16; 95% CI, 0.10 to 0.26; P < .001; supplemental Figure 1). Fondaparinux reduced the risk of extension to ≤3 cm from the SFJ by the same magnitude, from 3.6% to 0.3% (n = 5/1502; relative risk fondaparinux vs placebo: 0.09; 95% CI, 0.04 to 0.23; P < .001) and from 3.7% to 0.8% (n = 12/1502; relative risk fondaparinux vs placebo: 0.21; 95% CI, 0.12 to 0.40; P < .001), respectively (supplemental Figure 1). Eight of the 12 episodes of symptomatic extension to >3 cm from the SFJ in the fondaparinux group had occurred by day 47.

Compared with placebo, fondaparinux was associated with reduced use of medical resources, particularly in terms of anticoagulant treatment at therapeutic dosage (0% vs 1.9%), surgery to treat SVT (0.5% vs 3.6%), and need for additional face-to-face visits (0.5% vs 3.9%) and hospitalizations (0.5% to 3.7%; supplemental Table 1). All 5 fondaparinux-treated patients with SVT extension to ≤3 cm from the SFJ underwent surgery for superficial-vein thrombosis, whereas 7 of the 12 fondaparinux-treated patients with SVT extension to >3 cm from the SFJ did not undergo anticoagulant treatment or surgery. None of the fondaparinux-treated patients presenting symptomatic SVT extension, whether to ≤3 cm or to >3 cm from the SFJ, experienced subsequent deep-vein thrombosis or pulmonary embolism (supplemental Figure 2).

Overall, fondaparinux reduced the rate of any symptomatic thromboembolic complication up to day 77 by 79%, from 9.4% (141 of 1500 patients) in the placebo group to 1.9% (29 of 1502 patients; relative risk: 0.21; 95% CI, 0.14 to 0.30; P < .001; number needed to treat: 13; Figure 2).

**Discussion**

The placebo group of the CALISTO study, comprising 1500 patients, represents the largest series of untreated patients with spontaneous, acute, symptomatic SVT of the legs, without deep-vein thrombosis or pulmonary embolism at presentation, allowing description of the natural history of the disease. Although derived from a post hoc analysis, our findings are based on prospectively collected data on objectively confirmed symptomatic events validated by a blinded adjudication committee. The main finding of the present study is that symptomatic extension of the index SVT is a common complication in these patients, associated with an increased risk of subsequent deep-vein thrombosis or pulmonary embolism and greater consumption of medical resources, irrespective of the distance of the thrombus head from the SFJ at diagnosis of the extension. Compared with placebo, fondaparinux significantly reduced the risk of symptomatic extensions and subsequent symptomatic venous thromboembolic events and was associated with lower use of additional medical resources.
Contiguous propagation of the thrombotic process from a superficial vein into a deep vein via the SFJ, the sapheno-popliteal junction, or a perforating vein is probably the main mechanism underlying the association between SVT of the legs and deep-vein thrombosis or pulmonary embolism.7,8,17,18 As the great saphenous vein is the most frequent location of spontaneous SVT of the leg13 (more than 92% in CALISTO5), the SFJ connecting the great saphenous vein to the common femoral vein, extension of a SVT to within 3 cm from this junction may be considered as serious as a proximal deep-vein femoral vein, extension of a SVT to within 3 cm from any other location can be considered as serious as pulmonary embolism. Our study shows that the 3-cm limit acknowledged as the SFJ, respectively, suggests that the 3-cm limit acknowledged as the SFJ, respectively, might be artificial. Our data support the exclusion of patients in the highest risk category for thromboembolic complications (such as those with active cancer or recent venous thromboembolism) from the CALISTO study, to avoid their potential exposure to treatment with a placebo. Moreover, as patients in the CALISTO study underwent close clinical monitoring (probably more intensive than that likely in a real-life setting), most SVT extensions were probably detected early on, that is, before their propagation into the deep venous system.

Spontaneous SVT of the legs has long been regarded as a benign, self-limiting disease, usually expected to resolve spontaneously within a few weeks.1,16 During the last 3 decades, however, several studies have shown that it can be associated with a significant risk of thromboembolic complications, including deep-vein thrombosis, pulmonary embolism, and extension or recurrence of the index event, even in patients receiving anticoagulant treatments.2-4,12,17 Our study confirms these findings, with a 9.4% rate of such objectively confirmed symptomatic thromboembolic complications in untreated patients at day 77, including a 7.3% rate of symptomatic SVT extensions. These high rates were observed despite the exclusion of patients in the highest risk category for thromboembolic complications (such as those with active cancer or recent venous thromboembolism) from the CALISTO study, to avoid their potential exposure to treatment with a placebo. Moreover, as patients in the CALISTO study underwent close clinical monitoring (probably more intensive than that likely in a real-life setting), most SVT extensions were probably detected early on, that is, before their propagation into the deep venous system.

Table 1. Management of patients with symptomatic SVT extension up to day 77 in the placebo group of the CALISTO study

<table>
<thead>
<tr>
<th>Treatment received during the study, no. (%)</th>
<th>Extension to ≤3 cm from the SFJ</th>
<th>Extension to &gt;3 cm from the SFJ</th>
</tr>
</thead>
<tbody>
<tr>
<td>Graduated compression stockings</td>
<td>46 (3.1)</td>
<td>51 (3.4)</td>
</tr>
<tr>
<td>Analgesic agents</td>
<td>16 (1.1)</td>
<td>22 (1.5)</td>
</tr>
<tr>
<td>Topical nonsteroidal antiinflammatory drugs</td>
<td>17 (1.1)</td>
<td>30 (2.0)</td>
</tr>
<tr>
<td>Topical anticoagulant drugs</td>
<td>5 (0.3)</td>
<td>8 (0.5)</td>
</tr>
<tr>
<td>Oral nonsteroidal antiinflammatory drugs/anti-cox 2</td>
<td>12 (0.8)</td>
<td>13 (0.9)</td>
</tr>
<tr>
<td>Aspirin or other antiplatelet agents</td>
<td>17 (1.1)</td>
<td>15 (1.0)</td>
</tr>
<tr>
<td>Anticoagulant treatment*</td>
<td>29 (1.9)</td>
<td>30 (2.0)</td>
</tr>
<tr>
<td>High (therapeutic dose)</td>
<td>19 (1.3)</td>
<td>17 (1.1)</td>
</tr>
<tr>
<td>Intermediate dose</td>
<td>1 (0.1)</td>
<td>2 (0.1)</td>
</tr>
<tr>
<td>Low (prophylactic)</td>
<td>14 (0.9)</td>
<td>14 (0.9)</td>
</tr>
<tr>
<td>Unknown dose</td>
<td>1 (0.1)</td>
<td>1 (0.1)</td>
</tr>
<tr>
<td>Face-to-face visit after event diagnosis (in addition to those planned by the protocol), no. (%)</td>
<td>34 (2.3)</td>
<td>24 (1.6)</td>
</tr>
<tr>
<td>Compression ultrasonography to follow up this event after diagnosis, no. (%)</td>
<td>19 (1.3)</td>
<td>29 (1.9)</td>
</tr>
<tr>
<td>Hospitalization after event diagnosis, no. (%)</td>
<td>33 (2.2)</td>
<td>22 (1.5)</td>
</tr>
<tr>
<td>Duration, days (mean ± standard deviation)</td>
<td>6.4 ± 6.3</td>
<td>6.6 ± 4.3</td>
</tr>
<tr>
<td>Surgery to treat SVT, no. (%)†</td>
<td>34 (2.3)</td>
<td>20 (1.3)</td>
</tr>
<tr>
<td>No surgery to treat SVT, no. (%)</td>
<td>19 (1.3)</td>
<td>36 (2.4)</td>
</tr>
<tr>
<td>and no anticoagulant treatment either</td>
<td>6 (0.4)</td>
<td>14 (0.9)</td>
</tr>
</tbody>
</table>

*Patients with SVT to ≤3 cm from the SFJ; ligation of the sapheno-femoral or sapheno-popliteal junction in 31 and local thrombectomy in 3; patients with SVT to >3 cm from the SFJ; ligation of the sapheno-femoral or sapheno-popliteal junction in 18, local thrombectomy in 1, and varicose vein stripping within the great saphenous vein in 1.

†Patients with SVT to ≤3 cm from the SFJ; ligation of the sapheno-femoral or sapheno-popliteal junction in 31 and local thrombectomy in 3; patients with SVT to >3 cm from the SFJ; ligation of the sapheno-femoral or sapheno-popliteal junction in 18, local thrombectomy in 1, and varicose vein stripping within the great saphenous vein in 1.

For personal use only. by guest on November 22, 2013. bloodjournal.hematologylibrary.orgFrom bloodjournal.hematologylibrary.org by guest on November 22, 2013. For personal use only.
might be to propose monitoring of extensions using serial ultrasonography. In CALISTO, ultrasonography was permitted only to confirm symptomatic events, and systematic ultrasound examinations were discouraged. Nevertheless, we believe that serial ultrasonography is not the ideal management strategy for 2 reasons: (1) it was shown to be neither efficient nor cost effective in a series of patients with spontaneous acute symptomatic SVT of the legs, without deep-vein thrombosis or pulmonary embolism at presentation, and (2) in our study, fondaparinux was effective in reducing, by the same magnitude, the incidence of any type of SVT extension, the resulting morbidity, and the related use of additional medical resources, with no serial ultrasonographic monitoring.

Overall, this study supports the common knowledge that extension of SVT involving the SFJ is a clinically important event. Moreover, it shows that symptomatic extensions not reaching the SFJ are common and also associated with a significant risk of subsequent deep-vein thrombosis or pulmonary embolism, suggesting that more aggressive therapeutic strategies (anticoagulant treatment and/or surgery) is needed in these patients. Fondaparinux consistently decreased the risk of symptomatic extensions irrespective of the distance of the head of the thrombus from the SFJ as well as subsequent venous thromboembolic complications. In addition, fondaparinux was associated with reduced consumption of medical resources, an additional benefit to be taken into account when evaluating the cost effectiveness of this drug in the treatment of spontaneous, acute, symptomatic SVT of the legs.

This study was supported by a grant from GlaxoSmithKline.

Authorship

Contribution: A steering committee was responsible for the design, conduct, and reporting of the CALISTO study; data were collected and analyzed by the study sponsor; an independent central adjudication committee managed the database of adjudicated outcomes; A.L., P.P., and H.D. served on the steering committee; F.B. served on the central adjudication committee and was chair of the compression ultrasonography validation committee; I.Q. was the national coordinator in France and enrolled patients; all authors contributed to the design of this post hoc analysis; had full access to the data and analyses; contributed to interpreting the data and developing the report; agreed on the final version of the manuscript; and vouch for the report’s accuracy and completeness.

Conflict-of-interest disclosure: A.L. reports having received research grant support from Bristol-Myers Squibb and fees for board memberships from Bayer Pharmaceuticals, Boehringer Ingelheim, GlaxoSmithKline, and Sanofi-Aventis. F.B. reports having received honoraria for his participation in the compression ultrasonography validation committee. I.Q. reports having received honoraria from GlaxoSmithKline for participation in this study as an investigator and for having presented the study data. P.P. reports having received research grant support and consultancy fees from GlaxoSmithKline.

This study was supported by a grant from GlaxoSmithKline.

Acknowledgments

The authors are indebted to Dr Jean-Yves Darmon (MediBridge, France) who provided drafts and editorial assistance to the authors during preparation of this manuscript, supported by funding from GlaxoSmithKline.

Figure 2. Overall thromboembolic complication at day 77 in patients with SVT.
References


